The main area of expertise of the Breast Cancer Group is clinical research focused on drug development and associated translational…

We focus on proof-of-concept and proof-of-mechanism trials with targeted therapies, with particular emphasis on cell signaling, cancer stem cells, and…

Our group continues to play an essential role in developing molecular therapies against GI malignancies. We make important contributions to…

Our group focuses on better understanding the naturally occurring T-cell response to cancer and establishing ways to exploit these antitumor…

Our group focuses on the interplay between stress responses, cellular plasticity and cancer. Cellular plasticity is recognized today as a…

Our group conducts bench-to-bedside preclinical research in breast cancer to advance insights into biomarkers of response to targeted therapies. To…

We study primary brain tumors and brain metastasis; some of the most aggressive of all cancers. Both glioblastoma and brain…

We focus our research on mechanisms of resistance to targeted therapies and most importantly, how to overcome it by showing…

Our group focuses on the pleiotropic and ubiquitous Myc oncoprotein, whose deregulation is implicated in almost all human cancers. The…

Over the last decade, we have witnessed a revolution in the treatment of metastatic castration-resistant prostate cancer (mCRPC) which is…

Our group focuses on the study of sarcomas with oncogenic dependency on specific drivers of disease. Among these, gastrointestinal stromal…

Our group studies the mechanisms that enable tumors to evade effective treatments and progress to advanced stages.

VHIO’s Experimental Hematology Group conducts translational, pre-clinical and clinical research on hematological neoplasms of both lymphoid and myeloid origin. Our…

Our clinical research group focuses on gynecological malignancies and the development of novel therapies against these tumor types. We are…

VHIO’s ODysSey Group promotes translational research in precision oncology by integrating cancer molecular profiling data with clinical outcomes of oncology…

Focused on applying imaging biomarkers and radiomics to cancer discovery, our efforts center on advancing precision imaging in personalized medicine…

Our group is dedicated to advancing cancer treatment and care for patients suffering from thoracic malignancies, including lung cancer, mesothelioma…

We focus on the clinical development of PARP inhibitors (PARPi) in early gBRCA1/2 breast cancer, and novel combinations in the…